Skip to main content

NEWSBRIEF: Myriad Genetics Sees Revenue Rise, Widened Losses in Q3

SAN FRANCISCO, May 7 - Myriad Genetics today reported increased revenue and widened losses for the third quarter of fiscal 2002.


Total revenue for the third quarter ended March 31 was $13.1 million compared with $11.6 million in the year-ago period.


The net loss for the quarter was $3.5 million, or $.15 per share, compared to $1.7 million, or $.07 a share, for the same period a year ago.

R&D spending for the quarter rose to approximately $8.7 million from $8.4 million for the year-ago period. 


The company said it had $125.7 million in cash and investments as of March 31.


Click here for more information.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.